person · Reporting owner
Sullivan Christopher Ryan
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Financial Officer | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,900 |
Ending reported balance
After 2026-09-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-16 · Exercise / conversion · Acquired 12,394 · Balance 52,294 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. Row 2 · 2026-09-16 · Sale · Disposed 12,394 · Balance 39,900 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F2: The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.88 · Expires 2034-08-13 | Direct | 83,848 |
Reported balance
After 2026-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-16 · Exercise / conversion · Disposed 12,394 · Balance 83,848 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F3: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
F2: The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F3: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,394 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001810417-26-000023 · form4-09182026_040901.xml · derivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,848 Underlying: Common Stock · 12,394 shares Expires 2034-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F3 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 12,394 | $16.33 | $202,437.40 |
DisclosureSEC source: 0001810417-26-000023 · form4-09182026_040901.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,900 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 12,394 | $9.88 | $122,452.72 |
DisclosureSEC source: 0001810417-26-000023 · form4-09182026_040901.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,185 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001810417-26-000021 · form4-09112026_040901.xml · derivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,815 Underlying: Common Stock · 10,185 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F3 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 10,185 | $17.62 | $179,456.64 |
DisclosureSEC source: 0001810417-26-000021 · form4-09112026_040901.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,900 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 10,185 | $8.04 | $81,887.40 |
DisclosureSEC source: 0001810417-26-000021 · form4-09112026_040901.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,031 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · derivative · entry 9 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,242 Underlying: Common Stock · 31,031 shares Expires 2034-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 31,031 | $20.05 | $622,323.60 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · nonDerivative · entry 6 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,900 F4 · price: The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 18, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 31,031 | $9.88 | $306,586.28 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · nonDerivative · entry 5 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,876 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · derivative · entry 8 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,273 Underlying: Common Stock · 2,876 shares Expires 2034-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 37,945 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · derivative · entry 7 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,149 Underlying: Common Stock · 37,945 shares Expires 2034-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F5 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 3,749 | $19.94 | $74,762.18 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · nonDerivative · entry 4 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,900 F3 · price: The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 37,945 | $19.85 | $753,333.47 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · nonDerivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,649 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 2,876 | $9.88 | $28,414.88 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 37,945 | $9.88 | $374,896.60 |
DisclosureSEC source: 0001810417-26-000019 · form4-08192026_040813.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:36 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 138 | $13.10 | $1,807.80 |
DisclosureSEC source: 0001810417-26-000016 · form4-06122026_080641.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,773 F1 · balance_after: Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantCommon Stock | 39,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001810417-26-000014 · form4-05262026_040507.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,323 F1 · kind: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,606 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001810417-26-000012 · form4-05112026_040503.xml · derivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,094 Underlying: Common Stock · 18,606 shares Expires 2034-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F3 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 18,606 | $24.12 | $448,817.65 |
DisclosureSEC source: 0001810417-26-000012 · form4-05112026_040503.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 18,606 | $9.88 | $183,827.28 |
DisclosureSEC source: 0001810417-26-000012 · form4-05112026_040503.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001810417-26-000010 · form4-05072026_080542.xml · derivative · entry 7 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,000 Underlying: Common Stock · 47,000 shares Expires 2035-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F7 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 8,900 | $22.57 | $200,913.05 |
DisclosureSEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 6 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F6 · price: The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 9,219 | $21.37 | $197,008.19 |
DisclosureSEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 5 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,323 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F5 · price: The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 2,700 | $20.76 | $56,052.00 |
DisclosureSEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 4 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,542 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F4 · price: The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 12,347 | $19.28 | $238,093.37 |
DisclosureSEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,242 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F3 · price: The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 13,834 | $18.55 | $256,655.29 |
DisclosureSEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,589 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:16 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 47,000 | $8.04 | $377,880.00 |
DisclosureSEC source: 0001810417-26-000010 · form4-05072026_080542.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:37 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 8,457 | $13.23 | $111,853.13 |
DisclosureSEC source: 0001810417-26-000008 · form4-05012026_080546.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F3 · price: The reported securities were sold in multiple transactions at prices ranging from $12.61 to $13.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:37 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 8,458 | $13.09 | $110,736.37 |
DisclosureSEC source: 0001810417-26-000008 · form4-05012026_080546.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,880 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $12.74 to $13.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 19:14 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 1,780 | $17.57 | $31,269.97 |
DisclosureSEC source: 0001810417-26-000006 · form4-04032026_070439.xml · nonDerivative · entry 4 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,338 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F5 · price: The reported securities were sold in multiple transactions at prices ranging from $17.39 to $17.80. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 19:14 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 6,200 | $17.02 | $105,553.14 |
DisclosureSEC source: 0001810417-26-000006 · form4-04032026_070439.xml · nonDerivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,118 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F4 · price: The reported securities were sold in multiple transactions at prices ranging from $16.385 to $17.37. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 19:14 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 7,479 | $16.83 | $125,840.91 |
DisclosureSEC source: 0001810417-26-000006 · form4-04032026_070439.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,318 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F3 · price: The reported securities were sold in multiple transactions at prices ranging from $16.45 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 19:14 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | SaleCommon Stock | 500 | $15.86 | $7,929.00 |
DisclosureSEC source: 0001810417-26-000006 · form4-04032026_070439.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,797 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. F2 · price: The reported securities were sold in multiple transactions at prices ranging from $15.24 to $16.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionRestricted Stock Units · Derivative | 24,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001810417-26-000004 · form4-03312026_080330.xml · derivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,200 Underlying: Common Stock · 24,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F2 · derivative.expiration_date: On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 8,241 | $13.89 | $114,467.49 |
DisclosureSEC source: 0001810417-26-000004 · form4-03312026_080330.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,297 Read SEC document |
| March 28, 2026 Filed Mar 31, 2026 20:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 24,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001810417-26-000004 · form4-03312026_080330.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:22 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $17.64 | $0.00 |
DisclosureSEC source: 0001810417-26-000002 · form4-03022026_090301.xml · derivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on February 26, 2027 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 10, 2025 Filed Dec 12, 2025 21:17 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 155 | $4.10 | $635.50 |
DisclosureSEC source: 0001470831-25-000409 · form4.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,338 F1 · balance_after: Includes 417 additional shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionRestricted Stock Units · Derivative | 24,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000198 · primary_doc.xml · derivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,400 Underlying: Common Stock · 24,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F2 · derivative.expiration_date: On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Tax withholdingCommon Stock | 7,285 | $8.46 | $61,631.10 |
DisclosureSEC source: 0001578563-25-000198 · primary_doc.xml · nonDerivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,921 Read SEC document |
| March 28, 2025 Filed Apr 1, 2025 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | Exercise / conversionCommon Stock | 24,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-25-000198 · primary_doc.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 22:43 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 163,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001578563-25-000028 · primary_doc.xml · derivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,000 Underlying: Common Stock · 163,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantRestricted Stock Units · Derivative | 72,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000364 · primary_doc.xml · derivative · entry 3 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,600 Underlying: Common Stock · 72,600 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock upon the vesting date. F3 · derivative.exercise_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. F3 · derivative.expiration_date: The RSUs vest 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:11 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 186,700 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001578563-24-000364 · primary_doc.xml · derivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,700 Underlying: Common Stock · 186,700 shares Expires 2034-08-13 F1 · derivative.exercise_date: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:41 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 511 | $3.42 | $1,747.62 |
DisclosureSEC source: 0001628280-23-021962 · wk-form4_1686688870.xml · nonDerivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,262 F1 · shares: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan. Read SEC document |
| May 15, 2023 Filed May 17, 2023 11:44 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001628280-23-018557 · wk-form4_1684323885.xml · derivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-05-15 F1 · derivative.exercise_date: The stock option will vest in full on May 15, 2024, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:19 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001628280-23-003708 · wf-form4_167649596254341.xml · derivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:01 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001628280-22-026157 · wf-form4_166517288861221.xml · derivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-10-05 F1 · derivative.exercise_date: The stock option will vest in full on October 5, 2023, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:50 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001578563-22-000006 · primary_doc.xml · derivative · entry 2 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-08 F2 · derivative.exercise_date: The stock option will vest in full on March 8, 2023, subject to the Reporting Person's continued service through the vesting date. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 22:50 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001578563-22-000006 · primary_doc.xml · derivative · entry 1 Sullivan Christopher Ryan · CIK 0001810417 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-03-08 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.